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Background: Endometriosis is a benign chronic gynecological disease that affects women of reproductive age,
characterized by the presence of functional endometrial tissues outside the uterine cavity. GnRH agonists exhibit
anti-proliferative and apoptosis-enhancing activities and have long been used for the treatment of endometriosis. There is
a critical need to identify the signaling modules involving GnRH agonist therapy for the treatment of endometriosis. In this
study, we compared the proteomic profiles of endometriosis in patients before and after GnRH agonist therapy to identify
proteins that might provide further information concerning the mechanisms underlying the functions of GnRH agonists.
Methods: A total of 55 protein spots with different abundances were observed using Difference Gel Electrophoresis
(DIGE), and 26 of these proteins were assigned clear identities through Matrix-Assisted Laser Desorption/Ionization
Time-of-Flight Tandem Mass Spectroscopy (MALDI-TOF/TOF MS).
Results: We validated four of these proteins through Western blotting and immunohistochemistry using human
endometrial tissue. We also characterized the effect of Leuprolide acetate (LA) on the apoptosis of eutopic endometrial
epithelial cells. LA treatment significantly promoted the apoptosis of eutopic endometrial epithelial cells and inhibited
the expression of the anti-apoptotic factor GRP78. GRP78 knockdown enhanced LA-induced cell apoptosis, whereas,
the overexpression of GRP78 in eutopic endometrial epithelial cells suppresses LA-induced apoptosis.
Conclusion: These results suggest that GnRH agonists induce endometrial epithelial cell apoptosis via GRP78
down-regulation. This study might provide an important molecular framework for further evaluation of GnRH
agonist therapy.
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Endometriosis is a common benign chronic gynecological
disease in which functioning endometrial glands and
stroma are improperly present at sites outside the uterine
cavity. This disease affects 5-15% of women of reproduct-
ive age, causes pain and dyspareunia, and is frequently as-
sociated with infertility [1]. Although endometriosis was
first described in 1860, the etiology and pathogenesis of
this disease remain uncertain. Within the past few years,
important and promising advances have been made to-
wards the development of new approaches to limit symp-
toms and improve fertility [2]. The current treatments for* Correspondence: wyf1988@163.com
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unless otherwise stated.endometriosis primarily involve hormone suppressive
therapies that down-regulate the hypothalamus–pituitary–
ovarian pathway. These medical treatments effectively
relieve symptoms of pain, nevertheless endometriosis ex-
hibits a high recurrence rate and significant side effects,
such as hot flashes and genital atrophy, are observed from
the use of these medications [3].
Apoptosis, or programmed cell death, is a physiological
process that plays a critical role in maintaining tissue
homeostasis, killing unwanted cells without inducing im-
mune responses or inflammatory reactions [4]. Apoptosis
has been implicated in both normal development and dis-
ease [5]. Accumulating evidence suggests that apoptosis
maintains cellular homeostasis during the menstrual cycle
through the elimination of senescent cells from the func-
tional layer of the uterine endometrium during the late
secretory and menstrual phases of the cycle [6]. Thesetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Clinical characteristics of the patients enrolled in
this study




















Stages of endometriosis according to the Revised American Fertility Society
score (r-AFS). WB: Western blot analysis.
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used as a potential therapeutic strategy for the treatment
of endometriosis.
GnRH analogs (GnRHa) are the most widely used hor-
monal treatments for endometriosis [7]. Both GnRH and
GnRH receptors have been isolated from the eutopic and
ectopic endometrium, supporting a direct function for
GnRHa in endometrial growth [8]. Other studies have also
demonstrated that GnRHa induces apoptosis in both euto-
pic and ectopic endometrial cells from patients with endo-
metriosis [7]. Similarly, it has been shown that GnRHa
induces apoptosis and reduces cell proliferation in ovarian,
endometrial and breast cancer cell lines [8,9]. Neverthe-
less, the effect of GnRHa treatment on the eutopic endo-
metrium of patients with endometriosis and the activation
of apoptosis through these events remain unknown.
Proteomic analysis is a powerful screening method for
detecting unexpected changes in protein expression that
might be missed using conventional biochemical tech-
niques. Aside from accelerating diagnosis, the use of pro-
teomics has enhanced the current understanding of the
physiopathological progression of endometriosis through
the identification of proteins involved during different
stages [10]. In the present study, we compared the prote-
omic profiles of endometriosis in patients before and after
GnRH agonist therapy to identify proteins involved in the
mechanisms of GnRH agonist action. We detected 55 pro-
tein spots with different abundances via Difference Gel
Electrophoresis (DIGE), and 26 of these proteins were
assigned clear identities using MALDI-TOF/TOF MS.
Subsequently, we validated four of these proteins through
Western blotting and immunohistochemistry on human
endometrial tissue and investigated the effect of Leupro-
lide acetate on the apoptosis of eutopic endometrial epi-
thelial cells. Leuprolide acetate significantly promoted the
apoptosis of eutopic endometrial epithelial cells and inhib-
ited the expression of anti-apoptotic factor GRP78. These
results suggest that Leuprolide acetate induces endomet-




A total of 14 patients with endometrioma and pelvic endo-
metriosis were recruited from 2012 to 2013. The clinical
characteristics of the patients are shown in Table 1. Endo-
metriosis was determined laparoscopically. The severity of
endometriosis in all cases was classified according to the
Revised American Fertility Society rating (r-AFS; 1985).
Four stage III and ten stage IV were included in the
present study. This study was approved through the Ethics
and Research Committee of the Guangdong Women and
Children’s Hospital, Guangzhou, China. All subjects pro-
vided written informed consent.Endometrial tissues
Women with abnormal periods or exposure to steroids
within 3 months before surgery were excluded. The euto-
pic endometrium samples were collected through curet-
tage during laparoscopic surgery (control group, n = 14).
After surgery, GnRHa was administered as supplemen-
tal therapy to prevent recurrence. Each patient received
an intramuscular injection with 3.75 mg of Diphereline
(Triptorelin Acetate for injection, Ipsen, Pharma Biotech,
France) on the first day of the first menstruation after sur-
gery. On the 28th day after the first injection, the same pa-
tient underwent hysteroscopy, and a eutopic endometrium
sample was also collected.
Sample preparation
The samples were frozen in liquid nitrogen and preserved
at −80°C. The frozen endometrial tissue biopsy samples
were weighed (100 mg/mL lysis buffer) and immediately
thawed in phosphate-buffered saline solution on ice. The
tissues were washed five times with phosphate-buffered
saline solution to remove adhered hemoglobin. The dia-
lyzed samples were resuspended in Lysis Buffer (30 mM
Tris–HCl, 7 M urea, 2 M thiourea, and 4% CHAPS,
pH 8.5) and incubated on ice for 30 min. The suspensions
were sonicated on ice to prevent sample heating, and a
total of five 10-second bursts with 30-second pauses were
used. The lysates were subsequently centrifuged at
12,000 g for 30 minutes. The proteins were precipitated
from the suspension using the 2D Clean-up Kit (GE
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tions and resuspended in Lysis Buffer. The protein con-
centration was determined using the 2D Quant Kit (GE
Healthcare) according to the manufacturer’s instruc-
tions. The proteins were aliquoted followed by freezing
or freeze-drying. All reagents were obtained from the
Sigma Chemical Company unless otherwise noted.
Differential in-gel electrophoresis (DIGE)
For DIGE, 50 μg of protein were minimally labeled with
Cy Dyes at the ratio of 50 μg of protein: 400 pmol Cy3
or Cy5 protein-labeling dye (GE Healthcare) according
to the manufacturer’s instructions. Cy3 and Cy5 were
used to label the samples, and Cy2 was used for the in-
ternal standard (a pool of all samples). Each labeled sam-
ple was mixed with rehydration buffer (7 M urea, 2 M
thiourea, 4% CHAPS, 2% dithiothreitol, and 2% Pharma-
lyte; GE Healthcare) and applied to a 24-cm immobilized
pH gradient gel strip (immobilized pH gradient (IPG)
strip pH 3 to 10 NL) for separation in the first dimen-
sion. First-dimension isoelectric focusing was performed
at 20°C using the IPGphor III System (GE Healthcare)
and the following protocol: 30 V for 12 hours; 1,000 V
gradient for 2 hours; 8,000 V gradient for 2 hours; and
8,000 V for 60,00 volt-hours, followed by a 500 V hold.
After isoelectric focusing, the strips were equilibrated
through agitation for 15 minutes in 50 mM Tris–HCl,
pH 8.8, 6 M urea, 30% (v/v) glycerol, 2% (w/v) sodium
dodecyl sulfate (SDS) and 650 mM DTT, followed by
agitation for 15 min in 50 mM Tris–HCl, pH 8.8, 6 M
urea, 30% (v/v) glycerol, 2% (w/v) SDS and 1.27 M
iodoacetamide. The strips were subsequently loaded
onto a 24 × 24 cm 12% polyacrylamide gel using low
fluorescence glass plates and subjected to an electric
field in DALT Six (GE Healthcare; 15°C at a constant
3 W per gel for 12 hours in a running buffer containing
25 mM Tris, 192 mM glycine, and 0.1% (w/v) SDS). Sub-
sequently, the gels were scanned on a Typhoon 9400
imager (GE Healthcare) and analyzed using DeCyder 2D
Software V6.5 (GE Healthcare). The differentially expressed
protein spots observed between groups (filtering condi-
tions: at least 50% change of ratios between groups and t
test P <0.05) were considered for further examination. The
samples for the spot picking gel were prepared without Cy
dye labeling, and a 600 μg of pooled protein sample was
run on a preparative gel, followed by staining with colloidal
Coomassie Blue G-250. The matched spots were automat-
ically selected from the preparative gel using an Ettan Spot
Picker (GE Healthcare).
Protein identification
The selected spots were destained with 50% acetonitrile
(ACN)/100 mM NH4HCO3 for 10 min, dehydrated with
100% ACN for 10 min, and dried using a centrifugalconcentrator (TOMY SEIKO, Tokyo). Next, the gel slices
were incubated for 30 min at 4°C with 2 μL of 25 ng/mL
trypsin (Promega) diluted in 50 mM NH4HCO3. Subse-
quently, 30 μL of 50 mM NH4HCO3 was added, and the
spots were further incubated overnight at 37°C. We used
two solutions to extract the resulting peptide mixtures
from the gel slices. First, 100 μL of 60% (v/v) ACN in 0.1%
aqueous trifluoroacetic acid (TFA) was added, and the
mixture was sonicated for 15 min. Next, we collected the
solution and added 50 μL of 100% ACN for the final ex-
traction. The digested peptides were dried using a vacuum
pump, dissolved in 2 μL 50% acetonitrile/0.1% TFA, and
0.5 μL of the peptide sample was loaded onto the target
disk and air-dried. Subsequently, 0.5 μL of matrix solution
(CHCA saturated in 50% acetonitrile/0.1% TFA) was
added to the dried samples and dried. The samples on the
MALDI target plates were analyzed using an ABI 4800
Proteomics Analyzer MALDI-TOF/TOF mass spectrom-
eter (Applied Biosystems). A total of 800 shots were accu-
mulated for MS analyses. The MS/MS analyses were
performed using air, at 2-KV collision energy. The MAS-
COT search engine (version 2.1, Matrix Science) was used
to search the tandem mass spectra. GPS Explorer™ soft-
ware version 3.6.2 (Applied Biosystems) was used to create
and search files, and the MASCOT search engine was
used for peptide and protein identification against Swiss-
Prot non-redundant sequence databases selected for hu-
man taxonomy.
Western blot
The differentially expressed proteins, GRP78 (glucose-regu-
lated protein 78 kDa), PPA1 (pyrophosphatase (inorganic)
1), EFHA2 (EF-hand domain family, member A2), and
TGM2 (Protein-glutamine gamma-glutamyltransferase 2),
were further validated through Western Blot analysis, using
GAPDH (diluted 1:1000, Santa Cruz, USA) as the loading
control. Equal amounts of protein (50 μg), extracted from
10 samples as previously described, were loaded and sub-
jected to 12.5% SDS-PAGE. The proteins were subse-
quently transferred to PVDF membranes. The membranes
were blocked for 1 hour at room temperature in TBSTcon-
taining 5% skim milk. Rabbit polyclonal antibodies against
GRP78, PPA1, EFHA2 and TGM2 (diluted 1:1000, Santa
Cruz, USA) were used as primary antibodies. After washing
3 times with TBST for 5 min each time, the membranes
were incubated with each primary antibody at room
temperature for 2 hours. The membranes were washed
again, followed by incubation with a secondary peroxidase-
conjugated antibody (diluted 1:10000; Abcam, USA) for
1 hour at room temperature. After washing with TBST, the
reaction was detected through chemiluminescence using
ECL reagents (Forevergen Biosciences, China). The mem-
branes were exposed and scanned using a Carestream
Image Station 4000R (Carestream Health, USA). A semi-
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Quantity One software (Bio-Rad). Paired samples t-test was
used to determine the mean differences between the two
groups, and a P <0.05 was considered significant at a 95%
confidence level.
Immunohistochemistry
Ectopic and eutopic endometrial tissue sections were
fixed in 4% buffered paraformaldehyde in saline for 4 h
at 4°C and processed using standard procedures. Paraffin
sections (5 μm) were used for the immunohistochemical
localization of GRP78, PPA1, EFHA2, and TGM2 proteins.
The tissue sections were incubated overnight at 4°C with
appropriate concentrations of the specific antibodies ac-
cording to the manufacturer’s recommendations. Subse-
quently, the tissue sections were further incubated with the
secondary antibody (biotinylated IgG) for 45 min at room
temperature. Serum or IgG from the respective species with
reference to the primary antibody at the respective dilution
was used for the negative control. Visualization was
achieved using the Vectastain ABC Peroxidase Elite Kit
(Vector Laboratories, Burlingame, CA, USA) and freshly
prepared 3,3′-diaminobenzidine (DAB) tetrahydrochloride
(Sigma Chemical Company, St Louis, MO, USA) as aFigure 1 Triptorelin acetate induces eutopic endometrial epithelial ce
analysis of cleaved Caspase 3 in eutopic endometrial epithelial cells from e
assay to detect apoptosis in eutopic endometrial epithelial cells from endosubstrate. The staining intensity was quantified for each
protein using Image-pro Plus according to the manufac-
turer’s instructions (Media Cybernetics, Inc., Bethesda,
MD).
Apoptotic assay
For the in vivo apoptosis assay, eutopic endometrial tis-
sue sections were fixed in 4% paraformaldehyde for 24 h
at 4°C, washed in phosphate-buffered saline (PBS), and
embedded in paraffin blocks. The tissue sections were
incubated with proteinase K (20 μg/mL, without DNA-
ase), washed three times with HBSS, and subsequently
labeled using the TdT-FragEL™ DNA fragmentation de-
tection kit (Calbiochem), according to the manufac-
turer’s instructions. As a negative control, Tris-buffered
saline (TBS) was substituted for the TdT enzyme. Each
section was analyzed in at least 3 continuous fields of vi-
sion at high magnification, and the number of apoptotic
cells per 1,000 cells in each field was recorded. The
TUNEL-positive cells were counted from more than 10
areas and averaged in each anatomic region using high-
power-field (HPF, ×200) light microscopy.
For the in vitro apoptosis assay, the percentage of
apoptotic cells was also assessed through TUNEL inll apoptosis in patients with endometriosis. A. Western blot
ndometriosis patients after Triptorelin acetate treatment. B. TUNEL
metriosis patients after Triptorelin acetate treatment. *P <0.05.
Weng et al. Journal of Translational Medicine 2014, 12:306 Page 5 of 10
http://www.translational-medicine.com/content/12/1/306endometrial cultures under basal conditions and after
exposure to Leuprolide Acetate (LA) (25, 50, and
100 ng/mL).
Primary eutopic endometrial epithelial cell culture
The tissue was immediately placed in culture medium
and processed within 60 min of collection. The epithelial
cells were enzymatically separated and isolated through
successive centrifugation. The cells were maintained in
Dulbecco’s modified Eagle’s medium (DMEM)/F12
medium supplemented with 5% fetal bovine serum, 100
U/mL penicillin G and 100 g/mL streptomycin (Life
Technologies, Grand Island, NY, USA) at 37°C in a hu-
midified atmosphere of 5% CO2 and 95% air.
Transfection of GRP78 in eutopic endometrial
epithelial cells
After the cells reached 70-80% confluence, the medium
was removed and the cells were placed in serum-free
OPTI-MEM medium containing siRNA according to the
manufacturer’s instructions. Two small interfering (si)
RNAs targeting human GRP78 (siGRP78-1 and siGRP78-
2) were designed using the following primer sequences:
5′-CGACUCGAAUUCCAAAGAUdTdT-3′ and 5′-GAU
AAUCAACCAACUGUUAdTdT-3′, respectively. The
GRP78 protein expression in siRNA-transfected cells
was analyzed through Western blotting. To determine
whether GRP78 inhibits Leuprolide acetate-induced endo-
metrial epithelial cell apoptosis, eutopic endometrial epi-
thelial cells were seeded onto 6-well plates and transfected
the following day with pCMV-3X Flag-GRP78 or theFigure 2 2D-DIGE of eutopic endometrial proteins. Each individual sam
was labeled with Cy5, Cy3 and Cy2, respectively, mixed, and separated on
(C) images were obtained from each gel. An overlay of three dye-scannedpCMV-3X Flag vector alone using Lipofectamine 2000
(Invitrogen). The effect of GRP78 overexpression on Leu-
prolide acetate-induced endometrial epithelial cell apop-
tosis was assessed using a TUNEL assay.
Statistical analysis
The statistics features in DeCyder were used to evaluate
the results of the 2-DE gels. For all protein spots, the
GnRHa(+)/GnRHa(−) groups were compared, and the dif-
ferences were calculated as changes in the volume ratios
using Student’s t-test as selection criteria. The protein
spots with differential expression between the groups
(filtering conditions: at least 50% change of ratios between
groups and t-test P <0.05) were extracted. For western blot
(WB) analysis, paired samples t-test was used to determine
the mean differences between the two groups, and a
P <0.05 was used to assess the significance of these differ-
ences using SPSS13.0 software.
Results
GnRHa induces eutopic endometrial epithelial cell
apoptosis in patients with endometriosis
To characterize the signaling pathway in endometriosis
pathogenesis and the mechanisms underlying GnRHa
therapy, we determined the apoptosis levels in endometri-
osis before and after GnRHa treatment (by intramuscular
injection with Triptorelin Acetate) (Figure 1). Western
blot analysis showed that compared with the non-treated
control group, cleaved Caspase 3 expression in endometri-
osis patients after Triptorelin acetate treatment was higher
than that in GnRHa-control group. The results of theple (before and after GnRHa treatment) and internal reference sample
a 2D-PAGE gel. The gels were scanned, and Cy5 (A), Cy3 (B) and Cy2
images was also obtained (D).
Table 2 Eutopic endometrial proteins showing significant




MW (kDa) PI Ratio
(treat: control)
HSPA5 P11021(GRP78) 72.4 5.07 −4.17
HSP90B1 P14625 92.7 4.76 −3.74
CCT5 P48643 60.1 5.45 −2.67
PDIA6 Q15084 48.5 4.95 −2.39
LMNA P02545 74.4 6.57 −2.32
SASH1 O94885 137.7 5.78 −2.23
ALB P02768 71.3 5.92 −2.2
PPA1 Q15181 33.1 5.54 −2.11
HSPD1 P10809 61.2 5.7 −1.94
TMX1 Q9H3N1 32.2 4.92 −1.85
FGB P02675 56.6 8.54 −1.76
APOA1 P02647 30.8 5.56 −1.72
PDIA3 P30101 57.1 5.98 −1.7
DCN P07585 40.1 8.75 −1.6
PHB2 Q99623 33.3 9.83 1.55
KRT1 P04264 66.2 8.15 1.6
TPM4 P67936 28.6 4.67 1.68
FGG P02679 52.1 5.37 1.77
PRDX4 Q13162 30.7 5.86 1.78
TUBA1B P68363 50.8 4.94 1.92
FTL P02792 20.1 5.51 2.03
FGA P02671 95.7 5.7 2.21
EFHA2 Q86XE3 61 8.35 3.95
TGM2 P21980 78.4 5.11 4.69
SIGLEC16 A6NMB1 53.8 9.28 6.05
ACTG1 P63261 42.1 5.31 6.68
Weng et al. Journal of Translational Medicine 2014, 12:306 Page 6 of 10
http://www.translational-medicine.com/content/12/1/306TUNEL assay showed that the apoptotic rate in the
GnRHa-treated group was significantly higher compared
with the GnRHa non-treated group (P <0.05).
Proteomics assay
To analysis differentially expressed proteins in the eutopic
endometrium of endometriosis patients before and after
GnRHa treatment, we used 2-DE separation. Representa-
tive results are shown in Figure 2. A total of 55 protein
spots with different abundances were identified through
DIGE, of which 26 altered proteins were identified using
MALDI-TOF/TOF MS. A total of 12 proteins were up-
regulated and 14 proteins were down-regulated (Table 2).
These proteins included 6 secreted proteins, 4 cytoskeletal
proteins, 4 molecular chaperones, 4 proteins with catalytic
activity, 2 proteins involved in redox reactions, and 2 cell
membrane proteins to name a few. Actin, keratin, the
Tubulin alpha-1B chain and the Tropomyosin alpha-4
chain were among the cytoskeletal proteins identified.
Endoplasmin, a 78-kDa glucose-regulated protein, a 60-
kDa heat shock protein and T-complex protein 1 subunit
epsilon were among the molecular chaperones identified.
The proteins involved in redox reactions included
Peroxiredoxin-4 and Thioredoxin-related transmembrane
protein 1. After the first administration of GnRHa therapy,
Peroxiredoxin-4 protein was highly expressed. Moreover,
the cytoskeletal proteins were up-regulated, and the mo-
lecular chaperones were down-regulated.
Validation of selected candidates through
immunohistochemistry and western blotting
To validate the results of the DIGE analysis, four proteins,
selected on the basis of interesting biological functions and
expression changes, were examined in western blotting ex-
periments using commercially available specific antibodies
on protein extracts from endometriosis patients before and
after GnRHa treatment. As shown in Figure 3A, the levels
of GRP78 and PPA1 expression were higher in the
GnRHa- (untreated) group compared with the GnRHa +
(GnRHa-treated) group (P <0.05), while EFHA2 and
TGM2 expression significantly increased in endometriosis
patients after GnRHa treatment (P <0.05).
To further confirm the differential expression ob-
served in 2D-DIGE screening, we also performed immu-
nohistochemistry (IH) staining using paraffin sections.
As shown in Figure 3B, the results of IH were consist-
ent with the expression changes observed through 2D-
DIGE and western blot analysis.
Effects of GnRHa on epithelial cell apoptosis
For the in vitro functional analyses, Leuprolide Acetate
was used for GnRHa treatment because of its similar
common mechanism of action and pharmacological ef-
fects with Triptorelin and is widely use in similar studies[11,12]. The effects of different LA concentrations on
epithelial cell apoptosis are shown in Figures 4A and 4B.
Western blot analysis showed that cleaved Caspase 3 ex-
pression in epithelial cells after LA treatment was higher
than that in the control group. (Figure 4A). We also ob-
served that 25 ng/mL of LA enhanced epithelial cell
apoptosis from 2.33 ± 0.33 to 6.00 ± 0.58% (expressed as
a percentage of apoptotic cells, P <0.05) (Figure 4B), and
the concentration-dependent stimulation of cell apop-
tosis (6.00 ± 0.58, 12.33 ± 0.88, and 23.67 ± 1.76%) using
25, 50, and 100 ng/mL of LA, respectively, was also
observed.
GRP78 knockdown enhanced LA-induced cell apoptosis
GRP78 expression in isolated eutopic endometrial epithe-
lial cells before and after GnRHa treatment was detected
through Western blotting. As shown in Figure 5A, the
GRP78 expression after LA treatment was significantly
Figure 3 GRP78, PPA1, EFHA2, and TGM2 proteins expression in tissues before and after GnRHa treatment. A: Western blot analysis of 4
identified proteins (GRP78, PPA1, EFHA2, and TGM2) in eutopic endometrial epithelial tissues before and after GnRHa treatment (n = 10). The
statistical analysis of the protein expression levels in eutopic endometrial epithelial tissues is shown on the right. B: Immunohistochemical
detection of GRP78, PPA1, EFHA2, and TGM2 proteins in eutopic endometrial epithelial tissues before and after GnRHa treatment (n = 10).
*P <0.05.
Weng et al. Journal of Translational Medicine 2014, 12:306 Page 7 of 10
http://www.translational-medicine.com/content/12/1/306decreased in eutopic endometrial epithelial cells compared
with the control group. Figure 5B shows the expression of
GRP78 in scrambled control and GRP78 knockdown euto-
pic endometrial epithelial cells. GRP78 knockdown epithe-
lial cells exhibited lower GRP78 expression than the
scrambled control epithelial cells. We further evaluated
cell apoptosis after LA treatment in GRP78 knockdown
and scrambled control epithelial cells. The percentage
of apoptotic GRP78 knockdown cells (39.67 ± 6.11 and
42.33 ± 4.51 in siRNA-1 siRNA-2 cells, respectively) was
much higher in the scrambled control cells (25.33 ±
3.51, P <0.05) at 24 h after LA treatment (Figure 5B,
right). These results suggest that GRP78 is a target pro-
tein for LA-induced cell apoptosis in endometriosis.The overexpression of GRP78 in eutopic endometrial
epithelial cells suppresses LA-induced apoptosis
To determine whether GRP78 protects cells from LA-
induced apoptosis, we transfected pCMV-3 × Flag-GRP78
into eutopic endometrial epithelial cells to obtain the over-
expression of GRP78. Immunoblot analysis followed by
normalization against GAPDH revealed a 3-fold in-
crease in the level of GRP78 expression in transfected
cells compared with non-transfected cells (Figure 5C,
left). Although the overexpression of GRP78 did not
affect normal endometrial cell apoptosis, the percentage
of apoptotic GRP78-overexpressing cells (15.33 ± 2.08)
was much lower than that observed in the scrambled
control cells (26.00 ± 4.36).
Figure 4 Leuprolide acetate induces eutopic endometrial epithelial cell apoptosis. A: Leuprolide acetate (100 ng/mL) up-regulated the expression
of cleaved Caspase 3. B: Apoptosis detected through TUNEL staining. Compared with the normal group (untreated), the rate of apoptosis in eutopic
endometrial epithelial cells after treatment with 25, 50 and 100 ng/mL Leuprolide acetate was statistically significant. *P <0.05.
Weng et al. Journal of Translational Medicine 2014, 12:306 Page 8 of 10
http://www.translational-medicine.com/content/12/1/306Discussion
The eutopic endometrium of patients with endometriosis
is fundamentally different that of women without this dis-
ease. The apoptosis indices in the eutopic endometrium of
endometriosis patients were lower than those in women
without endometriosis [13]. The increased cell viability ob-
served in endometriosis reflects a reduction in cell death
through apoptosis and an increase in cell proliferation,
suggesting that this condition might facilitate the inva-
sive feature of the endometrium [14]. GnRH analogs en-
hanced EEC apoptosis, accompanied by an increase in
the expression of the pro-apoptotic proteins Bax and
FasL and a decrease in the expression of the anti-
apoptotic protein Bcl-2 [12]. These observed differences
suggest that the eutopic endometrium of women with
endometriosis is inherently aberrant and plays an im-
portant role in the pathogenesis of this disease [13,15].
GnRHa therapy has been widely used for the treatment
of estrogen-dependent disorders, such as endometriosis.
These compounds markedly suppress the gonadotropin
output from the pituitary gland, causing hypoestrogen-
ism and a reduction in the size of endometriotic lesions.
However, the local anti-proliferative effects of GnRHa
might act not only through the suppression of gonadal
steroids, but also through a direct effect on cell apop-
tosis [16]. There is strong evidence showing that GnRHa
directly induces the apoptosis of endometrial and several
types of cancer cells [7,12,17].In the present study, to validate the apoptosis-
promoting effect of GnRHa therapy on eutopic endomet-
rial epithelial cells, we determined the level of apoptosis in
endometriosis before and after GnRHa treatment. The re-
sults of Western blotting and TUNEL assays showed that
GnRHa induces eutopic endometrial epithelial cell apop-
tosis in patients with endometriosis. This finding is con-
sistent with Imai et al. [18], who reported that a GnRH
agonist triggered apoptosis in a single suspension of stro-
mal and glandular epithelial endometrial cells from pa-
tients with endometriosis and a recent study reporting
that GnRH-a stimulates apoptosis in endometrial cells
from patients with symptomatic myomas and this effect
could, at least in part, account for the therapeutic action
of GnRHa [19]. In addition, we also used epithelial human
endometrial cell cultures as a model to evaluate cell apop-
tosis in response to the addition of GnRHa. Exposure to
LA significantly increased the level of apoptosis in cell cul-
tures from patients and controls in a concentration-
dependent manner. Taken together, these results strongly
suggest that GnRHa might effectively promote the apop-
tosis of endometrial cells in vitro and in vivo.
Changes during and following GnRHa treatment in endo-
metriosis patients have been associated with the cell apop-
tosis. It have been shown that the apoptosis induced by
GnRHa in EEC is mediated by the Bax/Bcl-2 pathway [12].
However, there is little information regarding the involve-
ment of the proteome in this biological process. Herein,
Figure 5 Influence of GRP78 knockdown and overexpression on eutopic endometrial epithelial cells apoptosis. A: GRP78 expression in
separated eutopic endometrial epithelial cells before and after GnRHa treatment was detected through Western blotting. The statistical analysis of
the two groups showed obvious differences. *P <0.05 B: The GRP78 knockdown cells exhibited lower GRP78 expression than the control cells.
(Left) The knockdown of GRP78 did not affect normal endometrial cell apoptosis, while Leuprolide acetate treatment increased the percentage of
apoptosis in the GRP78 knockdown cells compared with the control cells (Right). Ctrl, cells without LA treatment; NC, cells transfected with
scrambled control; siRNA-1, cells transfected with siRNA-1 that targeting GRP78; siRNA-2, cells transfected with siRNA-2 that targeting GRP78.
*P <0.05 vs NC within the Ctrl goup, #P <0.05 vs NC within the LA goup. C: Comparison of the GRP78 protein levels in GRP78 overexpression and
control groups. (Left); GRP78 overexpression did not affect normal endometrial cell apoptosis, while GRP78 overexpression protected the cells
from Leuprolide acetate-induced apoptosis (Right). Ctrl, cells without LA treatment; NC, cells transfected with pCMV-3X Flag; GRP78, cells
transfected with pCMV-3X Flag-GRP78. *P <0.05 vs NC within the Ctrl goup, #P <0.05 vs NC within the LA goup.
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http://www.translational-medicine.com/content/12/1/306compared the levels of protein expression in the eutopic
endometrium of endometriosis patients before and after
GnRHa treatment using Western blotting and immuno-
chemistry and conducted a comprehensive proteomics ana-
lysis between GnRHa treated and control patients to
understand the molecular mechanisms underlying the ef-
fects of GnRHa on this disease. To our knowledge, this
study is the first to focus on the proteomics of the eutopic
endometrium in response to GnRHa therapy, showing evi-
dence of GnRHa-related protein changes in the eutopic
endometrium at a global level and in the same genotype.
Among the differentially expressed proteins identified in
the present study, 12 proteins were up-regulated, and 14
proteins were down-regulated. Most of these proteins weredescribed as differentially expressed in previous conven-
tional studies. We will discuss a few of these proteins.
GRP78 is a chief regulator of endoplasmic reticulum
(ER) function. GRP78 also acts as an anti-apoptotic factor
for protection against ER-stress-induced cell death. Conse-
quently, GRP78 is induced in a wide variety of cancer cells
and drug-resistant cancer cells [20]. Recent studies have
also indicated that ER stress alters GRP78 expression play-
ing an important role in the development and progression
of a variety of tumors. Moreover, the localization of
GRP78 to the plasma membrane suggest that this protein
might also play a role in endometrial cancer development
and progression, indicating a novel target for the treat-
ment of endometrial cancer [21]. Taken together, these
Weng et al. Journal of Translational Medicine 2014, 12:306 Page 10 of 10
http://www.translational-medicine.com/content/12/1/306studies indicate an important role for GRP78 in the treat-
ment of endometriosis.
Conclusion
The results of the present study showed that GRP78 ex-
pression is significantly decreased in eutopic endometrial
epithelial cells after LA treatment, and GRP78 knock-
down enhanced LA-induced cell apoptosis, while the
overexpression of GRP78 suppresses LA-induced apop-
tosis in eutopic endometrial epithelial cells. These results
suggest that GRP78 knockdown might be a useful in the
development of GnRHa drugs that promote endometrial
epithelial cell apoptosis.
Furthermore, these findings also suggest that GnRHa
might effectively promote the apoptosis of endometrial
cells both in vitro and in vivo, and induce endometrial
epithelial cell apoptosis through the downregulation of
GRP78. This knowledge could contribute to a better un-
derstanding of the mechanisms underlying the thera-
peutic action of GnRHa and the medical treatment of
endometriosis.
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